College of Nursing, Anhui University of Chinese Medicine, Hefei, China.
Medicine (Baltimore). 2024 Nov 29;103(48):e40705. doi: 10.1097/MD.0000000000040705.
To evaluate the short-term efficacy of denervation in treating hypertension with the exclusion of drug-interfering factors.
An electronic search was conducted across 8 databases, including MEDLINE, PubMed, Cochrane Library, and EMBASE, for articles on denervation in the treatment of medication-naïve hypertension published from inception to May 2024. All data were meta-analyzed using RevMan 5.3 software.
Four studies, comprising a total of 752 subjects, were screened according to the inclusion and exclusion criteria. Meta-analysis indicated that, compared to the sham-operated group, the denervation group showed a significant reduction in short-term 24-hour ambulatory systolic blood pressure and office systolic blood pressure (OSBP) as well as office diastolic blood pressure (ODBP). No significant safety events were identified.
Denervation has the potential to reduce blood pressure in the short-term for patients with medication-naïve hypertension, demonstrating an acceptable safety profile. This offers hope for patients who are intolerant to drug therapy or unwilling to take lifelong medication. However, its long-term effects require further study. Future research should focus on expanding the sample size and prolonging the follow-up period to further solidify its role in the treatment of hypertension.
评估去神经治疗药物干预因素排除后的高血压的短期疗效。
检索 MEDLINE、PubMed、Cochrane 图书馆和 EMBASE 等 8 个数据库，从建库至 2024 年 5 月，收集去神经治疗药物未治疗高血压的相关研究，采用 RevMan 5.3 软件进行荟萃分析。
根据纳入和排除标准，筛选出 4 项研究，共纳入 752 例患者。荟萃分析结果显示，与假手术组相比，去神经组的短期 24 小时动态收缩压和诊室收缩压（OSBP）以及诊室舒张压（ODBP）均显著降低。未发现明显的安全性事件。
去神经治疗可能在短期内降低药物未治疗高血压患者的血压，具有可接受的安全性。这为不能耐受药物治疗或不愿终身服药的患者带来了希望。但其长期疗效仍需进一步研究。未来的研究应扩大样本量并延长随访时间，以进一步明确其在高血压治疗中的作用。
